在美国，泰利霉素对大环内酯类敏感及耐药的A组链球菌咽部分离株的体外活性。
In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States.
作者信息
Green Michael, Allen Coburn, Bradley John, Dashefsky Barry, Gilsdorf Janet R, Marcon Mario J, Schutze Gordon E, Smith Clay, Walter Emmanuel, Martin Judith M, Edwards Kathryn A, Barbadora Karen A, Rumbaugh Renee M, Wald Ellen R
机构信息
Department of Pediatrics, MPH Division of Allergy, Immunology and Infectious Diseases, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA.
出版信息
Antimicrob Agents Chemother. 2005 Jun;49(6):2487-9. doi: 10.1128/AAC.49.6.2487-2489.2005.
Abstract
In vitro susceptibility testing of 2,797 group A streptococcus (GAS) isolates demonstrated that telithromycin was fully active against all macrolide-susceptible strains and among 80 of 115 macrolide-resistant GAS expressing the M phenotype. Telithromycin resistance was identified in 2 of 45 strains expressing the inducible macrolide-lincosamide-streptogramin B phenotype and four of nine isolates expressing the constitutive macrolide-lincosamide-streptogramin B resistance phenotype.
摘要
对2797株A群链球菌（GAS）分离株进行的体外药敏试验表明，泰利霉素对所有大环内酯类敏感菌株以及115株表达M表型的大环内酯类耐药GAS中的80株均具有完全活性。在45株表达诱导型大环内酯-林可酰胺-链阳菌素B表型的菌株中有2株以及9株表达组成型大环内酯-林可酰胺-链阳菌素B耐药表型的分离株中有4株鉴定出对泰利霉素耐药。
相似文献
1
In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States.在美国，泰利霉素对大环内酯类敏感及耐药的A组链球菌咽部分离株的体外活性。
Antimicrob Agents Chemother. 2005 Jun;49(6):2487-9. doi: 10.1128/AAC.49.6.2487-2489.2005.
2
Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004.2004年在西班牙分离出的化脓性链球菌对大环内酯类、克林霉素和替利霉素的耐药性
J Antimicrob Chemother. 2005 Oct;56(4):780-2. doi: 10.1093/jac/dki286. Epub 2005 Aug 24.
3
Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.16元环大环内酯类药物及泰利霉素对不同基因型的红霉素敏感及耐药化脓性链球菌和肺炎链球菌的活性。
J Antimicrob Chemother. 2007 Jun;59(6):1171-6. doi: 10.1093/jac/dkm089. Epub 2007 Apr 3.
4
5
Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.化脓性链球菌和肺炎链球菌对大环内酯类药物及泰利霉素的敏感性：一项意大利多中心研究的数据。
J Chemother. 2007 Oct;19(5):500-7. doi: 10.1179/joc.2007.19.5.500.
6
Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany.德国亚琛地区咽喉感染患者分离出的化脓性链球菌菌株中的大环内酯类耐药性
Microb Drug Resist. 2001 Summer;7(2):165-70. doi: 10.1089/10766290152045039.
7
In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.酮内酯类药物泰利霉素和HMR 3004对意大利不同红霉素敏感性的化脓性链球菌和肺炎链球菌分离株的体外活性
J Antimicrob Chemother. 2000 Dec;46(6):905-8. doi: 10.1093/jac/46.6.905.
8
Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations.具有高水平大环内酯类耐药性且对泰利霉素敏感性降低的化脓性链球菌分离株与23S rRNA突变有关。
Antimicrob Agents Chemother. 2006 Feb;50(2):817-8. doi: 10.1128/AAC.50.2.817-818.2006.
9
In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.新型酮内酯类药物泰利霉素与大环内酯类药物对化脓性链球菌的体外活性比较：耐药机制和方法学因素的影响
Antimicrob Agents Chemother. 2000 Nov;44(11):2999-3002. doi: 10.1128/AAC.44.11.2999-3002.2000.
10
Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania.宾夕法尼亚州西南部A组链球菌咽部分离株中大环内酯耐药性的再度出现。
Antimicrob Agents Chemother. 2004 Feb;48(2):473-6. doi: 10.1128/AAC.48.2.473-476.2004.
引用本文的文献
1
Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations.具有高水平大环内酯类耐药性且对泰利霉素敏感性降低的化脓性链球菌分离株与23S rRNA突变有关。
Antimicrob Agents Chemother. 2006 Feb;50(2):817-8. doi: 10.1128/AAC.50.2.817-818.2006.
本文引用的文献
1
Community-based surveillance in the united states of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons.美国在三个呼吸道疾病季节对耐大环内酯类儿科A组咽型链球菌进行的基于社区的监测。
Clin Infect Dis. 2004 Dec 15;39(12):1794-801. doi: 10.1086/426025. Epub 2004 Nov 18.
2
Mutation at the position 2058 of the 23S rRNA as a cause of macrolide resistance in Streptococcus pyogenes.23S rRNA第2058位的突变是化脓性链球菌大环内酯耐药的原因。
Ann Clin Microbiol Antimicrob. 2004 May 6;3:5. doi: 10.1186/1476-0711-3-5.
3
In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance.新型酮内酯类药物泰利霉素及其他8种大环内酯类抗生素对携带介导大环内酯类耐药的mefA和ermB基因的肺炎链球菌的体外活性。
J Infect Chemother. 2003 Sep;9(3):221-6. doi: 10.1007/s10156-003-0258-2.
4
Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data.化脓性链球菌临床分离株对泰利霉素和奎奴普丁-达福普汀的耐药性：SMART项目2001年数据。
Antimicrob Agents Chemother. 2003 Jul;47(7):2152-7. doi: 10.1128/AAC.47.7.2152-2157.2003.
5
Macrolide resistance in group A Streptococcus.
Pediatr Infect Dis J. 2002 Dec;21(12):1158-60. doi: 10.1097/00006454-200212000-00015.
6
Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.从1999 - 2000年PROTEKT研究中分离出的肺炎链球菌和化脓性链球菌大环内酯类耐药机制的分子特征
J Antimicrob Chemother. 2002 Sep;50 Suppl S1:39-47. doi: 10.1093/jac/dkf806.
7
Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia.在俄罗斯，与其他七种药物相比，泰利霉素针对大环内酯类耐药机制的抗链球菌活性。
Antimicrob Agents Chemother. 2002 Sep;46(9):2963-8. doi: 10.1128/AAC.46.9.2963-2968.2002.
8
In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.体内真相：全身性肺炎链球菌感染中体外大环内酯类耐药确实会导致临床治疗失败。
Clin Infect Dis. 2002 Sep 1;35(5):565-9. doi: 10.1086/341980. Epub 2002 Aug 9.
9
In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis.酮内酯类药物ABT-773和泰利霉素以及三种大环内酯类药物对肺炎链球菌、化脓性链球菌、流感嗜血杆菌和卡他莫拉菌基因特征明确的分离株的体外活性。
J Antimicrob Chemother. 2002 Jul;50(1):145-8. doi: 10.1093/jac/dkf085.
10
Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh.匹兹堡学童中对红霉素耐药的A组链球菌
N Engl J Med. 2002 Apr 18;346(16):1200-6. doi: 10.1056/NEJMoa013169.
Zotero 插件